



# Génétique cardiovasculaire: « Concepts & nouvelles approches »

**Jean-Jacques SCHOTT**

Directeur de recherche INSERM

Equipe I « Génétique HUMAINE »

([jjschott@univ-nantes.fr](mailto:jjschott@univ-nantes.fr))



L'unité de recherche de l'institut du thorax  
Inserm UMR 1087 / CNRS UMR 6291  
Nantes, France

MASTER 1 Thorax

Unité d'enseignement « Recherche en  
Physiopathologies humaines »

23-11-2023

# Translational approach to investigate cardiovascular diseases

*“FROM BEDSIDE TO BENCH TO BEDSIDE”*



Centre for  
Clinical Investigations  
(CIC ‘thorax’)

 Nantes  
Université

**Inserm 1087/CNRS 6291**  
**72 researchers**

4 Teams:

- Human Genetics
- Ion channels and cardiopathies
- Vascular & Pulmonary Diseases
- Cardiometabolic diseases



patients

600 people  
85 clinicians



bedside

*Improved patient care*



CENTRE HOSPITALIER  
UNIVERSITAIRE DE NANTES



l'institut  
du thorax

2004



bench

*Combining basic research  
and translational  
research programs*

# Research programs



Program I-1:  
Methods in biostatistics and  
bioinformatics

C. DINA, A. GAIGNARD, P. LINDENBAUM AND R. REDON



Program I-2:  
Cardiac arrhythmia

JULIEN BARC AND VINCENT PROBST



Program I-3:  
Congenital heart disease

ALBAN BARUTEAU AND JEAN-JACQUES SCHOTT



Program I-4:  
Cardiac valve disease

R. CAPOULADE, S. LE SCOUARNEC, J. MÉROT, J.J. SCHOTT AND T. LE TOURNEAU



Program I-5:  
Intracranial aneurysm

ROMAIN BOURCIER AND RICHARD REDON



Program I-6:  
Inherited erythrocytosis

BETTY GARDIE



Program I-7:  
Developmental disorders

STÉPHANE BÉZIEAU



# Approches génétique en 2023: objectifs

## 1- Concepts, outils & modèles: (Dynamique des génomes)

- Variants rares (→ ++ maladies mendéliennes)
  - Approches Liaison génétique – approches en famille (clonage positionnel)
  - Séquençage SANGER; séquençage d'exome (WES)
  - Séquençage de génomes complets (WGS) → accès à l'ensemble

**du spectre de fréquences alléliques des REGIONS CODANTES & NON CODANTES; épigénétique)**


- Variants fréquents
  - Etude d'association (GWAS); approches en population (Génotypage)  
→ augmentation du risque

## 2- Applications en Génétique Cardiovasculaire

- Troubles de conduction cardiaque de l'enfance
- Dysfonction sinusale - cardiomyopathie
- Troubles du rythme ventriculaire: **Le** syndrome de Brugada




# Disease gene identification allowed by a spectacular acceleration of knowledge of the architecture of the human genome



# A global reference for human genetic variation

The 1000 Genomes Project Consortium\*

- 2504 individuals from 26 different populations
- Broad spectrum of genetic variations:
  - 88 millions variants (MAF >1%)



**bioRxiv**  
THE PREPRINT SERVER FOR BIOLOGY

HOME | ABOUT | :

bioRxiv is receiving many new papers on coronavirus SARS-CoV-2. A reminder: these are preliminary reports that have not been peer-reviewed, and should not be used to guide clinical practice.

New Results

[Comment on this paper](#)

## High coverage whole genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios


Marta Byrska-Bishop, Uday S. Evani, Xuefang Zhao, Anna O. Basile, Haley J. Abel, Allison A. Regier, André Corvelo, Wayne E. Clarke, Rajeeva Musunuri, Kshithija Nagulapalli, Susan Fairley, Alexi Runnels, Lara Winterkorn, Ernesto Lowy-Gallego, The Human Genome Structural Variation Consortium, Paul Flicek, Soren Germer, Harrison Brand, Ira M. Hall, Michael E. Talkowski, Giuseppe Narzisi, Michael C. Zody

doi: <https://doi.org/10.1101/2021.02.06.430068>

This article is a preprint and has not been certified by peer review [what does this mean?].

du thorax

# Stratégies génétique & dynamique des génomes



Novembre & Ramachandran.

*Ann Rev Genomics Hum Genet* 12:245, 2011

- 1000 genome project (population)

- Bases de données : gnomAD, UK biobank (patients)



# Variants rares

MAF (fréquence de l'allèle mineur)  $< 0,1 \%$

Variations « récentes

Variants à effet fort

\*Approche familiale –Maladies Mendéliennes  
Souvent dans les gènes (exons)

## Variants fréquents

MAF < 5 %

→ Variations « anciennes » maintenues durant l'évolution

→ Approche en population – Maladies fréquentes

**« *Common variant – common disease* »**

Variants à effet faible


Augmentation du risque de développer une maladie  
d'environ 1- 5 %

Souvent dans les régions non codantes

Modulation de l'expression d'un gène

# Clonage positionnel : « génétique des grandes familles »

## Variants rares








# Modes de transmission

Mode de transmission	Localisation du locus responsable du trait	Principales caractéristiques	Exemples de phénotypes
Autosomique dominant	Chromosome 1-22	-hommes et femmes sont atteints avec une fréquence équivalente -les enfants atteints ont un parent atteint	Huntington, syndrome de Marfan
Autosomique récessif	Chromosome 1-22	-hommes et femmes sont atteints avec une fréquence équivalente -les enfants atteints n'ont pas de parent atteint -peut « sauter » une ou plusieurs générations	Mucoviscidose, drépanocytose
Dominant lié à l'X	Chromosome X	-les femmes atteintes ont 50% d'enfants atteints -les hommes sont plus sévèrement atteints -toutes les filles de père atteints sont atteintes	Syndrome de Rett
Récessif lié à l'X	Chromosome X	-beaucoup plus d'hommes atteints que de femmes -les hommes atteints ont une mère saine (porteuse) -le trait n'est jamais transmis de père à fils -peut « sauter » une ou plusieurs générations	Hémophilie
Lié à l'Y	Chromosome Y	-tous les hommes atteints passent le trait à leur fils -les femmes ne sont pas atteintes	Stérilité
Mitochondrial	Pas chromosomique ADN mitochondrial	-tous les enfants d'une femme atteinte sont atteints -les hommes atteints ne transmettent pas le trait	Neuropathie optique de Leber

# Clonage positionnel : Séquençage SANGER






# Effet des variants génétiques



- Effet de ces mutations variables selon la protéine
  - Haplo insuffisance (50 % de réduction d'activité)
  - Gain de fonction (ex. SCN5A /LQT3; fuite de courant sodique)
  - Effet dominant négatif (peptide poison; ex Canaux K<sup>+</sup>; structure α4)



# Next generation sequencing – massively parallel sequencing



➤ Exome sequencing: capture all coding regions of the genome 50 Mb (< 2% genome)

**Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes**  
Jacob A. Tennessen *et al.*  
*Science* **337**, 64 (2012);  
DOI: 10.1126/science.1219240






➤ Whole Genome: full spectrum of allelic variability & Copy Number Variations

➤ RNA-seq


➤ Epigenetic marks (ATAC-Seq...)

# Séquençage d'Exome (NGS)



Reference	..TTAGTAATAACAT--GTGCATCTTAAATC..
Read_01	..TTAGGAATAACAT <b>GC</b> GTGCA
Read_02	..TTAGGAATAACAT <b>GC</b> GTGCATCT
Read_03	..TTAGGAATAACAT <b>GC</b> GT <b>CC</b> ATCTT
Read_04	..TTAGGAATAACAT <b>GC</b> GTGCATCTTAAAT
Read_05	..TTAGGAATAACAT <b>GC</b> GTGCATCTTAAATC..
Read_06	..TTAGGAATAACAT <b>GC</b> GTGCATCTTAAATC..
Read_07	..TTAGGAATAACAT <b>GC</b> GTGCATCTTAAATC..
Read_08	AATAACAT <b>GC</b> GTGCATCTTAAATC..
Read_09	TAACAT <b>GC</b> GTGCATCTGTAATC..

# Variant Filtering



# Identification de variants rares causaux grâce aux nouvelles technologies de séquençage



## 1. Variants fonctionnels Variants non-synonymes et d'épissage

## 2. Variants rares Bases de données externes et internes

CRHOM	POSITION	REF	ALT
5	112175526	G	C
5	125820120	G	C
10	5138672	C	G

~ 85.000 variants

CRHOM	POSITION	REF	ALT
..	.....	..	..
22	16449042	T	A
5	56177051	C	G
5	75913610	C	T
6	10894103	C	T
9	102068277	A	C
9	112015730	T	C
1	897829	C	G
1	8415627	T	C
1	17722114	G	A
1	86173964	C	T
1	92765756	A	G
1	113238173	C	T
1	120458982	C	G
1	143378919	T	C
1	146639425	G	A
1	159002410	A	G
1	159021815	T	G
1	177250522	G	A
1	179012995	CAGGG	C
1	242022009	G	A
1	247463963	C	T
1	247492516	C	T
10	17083054	T	C
10	28233186	G	A
10	83635880	A	G
10	83992548	G	T
10	99377056	G	T
10	102265186	C	T
10	102778027	TCTC	T
10	116059031	G	C
10	121347832	C	A
10	127429028	A	G
11	1298431	G	A
11	1463811	G	A
11	1904753	A	G
11	3681258	G	C
11	6636687	G	A
11	27363105	A	C
11	34527245	C	T
11	46401474	G	A
11	55111661	TAA	T
11	55433325	C	T
11	59712732	G	A
11	62287110	C	T
11	63066440	T	G
11	64428387	C	T
11	67265077	C	T
11	73744718	C	A

CRHOM	POSITION	REF	ALT
5	112175526	G	C
5	125820120	G	C
10	5138672	C	G

~ 15 000 variants

CRHOM	POSITION	REF	ALT
..	.....	..	..
22	16449042	T	A
5	56177051	C	G
5	75913610	C	T
6	10894103	C	T
9	102068277	A	C
9	112015730	T	C
1	897829	C	G
1	8415627	T	C
1	17722114	G	A
1	86173964	C	T
1	92765756	A	G
1	113238173	C	T
1	120458982	C	G
1	143378919	T	C
1	146639425	G	A
1	159002410	A	G
1	159021815	T	G
1	177250522	G	A
1	179012995	CAGGG	C
1	242022009	G	A
1	247463963	C	T
1	247492516	C	T

CRHOM	POSITION	REF	ALT
5	112175526	G	C
5	125820120	G	C
..	.....	..	..

~ 200 variants

CRHOM	POSITION	REF	ALT
..	.....	..	..
18	31324584	G	A
1	247492516	C	T

# Identification de variants rares causaux grâce aux nouvelles technologies de séquençage



## 1. Variants fonctionnels Variants non-synonymes et d'épissage

## 2. Variants rares Bases de données externes et internes

CRHOM	POSITION	REF	ALT
5	112175526	G	C
5	125820120	G	C
10	5138672	C	G

~ 85.000 variants

CRHOM	POSITION	REF	ALT
..	.....	..	..
22	16449042	T	A
5	56177051	C	G
5	75913610	C	T
6	10894103	C	T
9	102068277	A	C
9	112015730	T	C
1	897829	C	G
1	8415627	T	C
1	17722114	G	A
1	86173964	C	T
1	92765756	A	G
1	113238173	C	T
1	120458982	C	G
1	143378919	T	C
1	146639425	G	A
1	159002410	A	G
1	159021815	T	G
1	177250522	G	A
1	179012995	CAGCG	C
1	242022009	G	A
1	247463963	C	T
1	247492516	C	T
10	17083054	T	C
10	28233186	G	A
10	83635880	A	G
10	83992548	G	T
10	99377056	G	T
10	102265186	C	T
10	102778027	TCTC	T
10	116059031	G	C
10	121347832	C	A
10	127429028	A	G
11	1298431	G	A
11	1463811	G	A
11	1904753	A	G
11	3681258	G	C
11	6636687	G	A
11	27363105	A	C
11	34527245	C	T
11	46401474	G	A
11	55111661	TAA	T
11	55433325	C	T
11	59712732	G	A
11	62287110	C	T
11	63066440	T	G
11	64428387	C	T
11	67265077	C	T
11	73744718	C	A

CRHOM	POSITION	REF	ALT
5	112175526	G	C
5	125820120	G	C
10	5138672	C	G

~ 15 000 variants

CRHOM	POSITION	REF	ALT
..	.....	..	..
22	16449042	T	A
5	56177051	C	G
5	75913610	C	T
6	10894103	C	T
9	102068277	A	C
9	112015730	T	C
1	897829	C	G
1	8415627	T	C
1	17722114	G	A
1	86173964	C	T
1	92765756	A	G
1	113238173	C	T
1	120458982	C	G
1	143378919	T	C
1	146639425	G	A
1	159002410	A	G
1	159021815	T	G
1	177250522	G	A
1	179012995	CAGCG	C
1	242022009	G	A
1	247463963	C	T
1	247492516	C	T

CRHOM	POSITION	REF	ALT
5	112175526	G	C
5	125820120	G	C
..	.....	..	..

~ 200 variants

CRHOM	POSITION	REF	ALT
..	.....	..	..
18	31324584	G	A
1	247492516	C	T

➤ Partagés par les individus atteints  
(cas familiaux)



➤ Liaison génétique

# gnomAD v4.0

## gnomAD v4.0

---

November 01, 2023 in [Announcements](#) / [Release](#)

[Katherine Chao](#), gnomAD Production Team

Today, we are delighted to announce the release of gnomAD v4, which includes data from 807,162 total individuals. This release is nearly **5x** larger than the combined v2/v3 releases and consists of two callsets: exome sequencing data from 730,947 individuals, including 416,555 individuals from the UK Biobank, and genome sequencing data from 76,215 individuals. Both callsets within v4 were aligned to build **GRCh38** of the human reference genome.

The gnomAD v4 release adds additional global diversity and includes **~138,000** individuals of non-European genetic ancestry. However, the new inclusion of cohorts such as the UK Biobank means that the proportion of samples with European ancestry is higher than in previous releases. The genetic ancestry group breakdown of gnomAD v4 is:

<https://gnomad.broadinstitute.org/news/2023-11-gnomad-v4-0/>



# UK Biobank is a large-scale biomedical database and research resource



Researcher log in

Participant log in

Contact us

Enable your research

Explore your participation

Learn more about UK Biobank



## Enabling your vision to improve public health


Data drives discovery. We have curated a uniquely powerful biomedical database that can be accessed globally for public health research. Explore data from half a million UK Biobank participants to enable new discoveries to improve public health.

Data Showcase

Future data releases

UK Biobank is a large-scale biomedical database and research resource, containing in-depth genetic and health information from half a million UK participants. The database is regularly augmented with additional data and is globally accessible to approved researchers undertaking vital research into the most common and life-threatening diseases. It is a major contributor to the advancement of modern medicine and treatment and has enabled several scientific discoveries that improve human health.

# Identification par séquençage d'exomes / génomes de variants rares



# Cardiac arrhythmia

➤ **Sudden Cardiac Death is a major health burden in industrialized countries**


➤ *Ventricular Fibrillation is the most common mechanism*

Myocardial infarction

Cardiomyopathy

~80%

~10%



Acute plaque destabilization



Hypertrophic Cardiomyopathy




Dilated Cardiomyopathy



## Primary electrical disorders


~10%



- ⇒ **Brugada syndrome**
- ⇒ **Early repolarization syndrome**
- ⇒ **Long QT Syndrome**
- ⇒ **Catecholaminergic Polymorphic Ventricular Tachycardia**
- ⇒ **Arrhythmogenic right ventricular cardiomyopathy**
- ⇒ **Sinus node dysfunction**
- ⇒ **Cardiac conduction defects**

**These electrical disorders provide a homogenous groups of patients with high risk for SCD, which can be considered as a 'sensitized model' for VF**

# Primary electrical cardiac disorders




Sick sinus syndrome

Atrial arrhythmias  
Atrial Fibrillation


Conduction defects  
Atrioventricular block

Ventricular arrhythmias  
Long QT syndrome  
Brugada Syndrome  
Early Repolarisation Syndrome

Family 1




Disease / phenotype threshold



..... Rare to



# Primary electrical cardiac disorders




Sick sinus syndrome

Atrial arrhythmias  
Atrial Fibrillation


Conduction defects  
Atrioventricular block

Ventricular arrhythmias  
Long QT syndrome  
Brugada Syndrome  
Early Repolarisation



■ BrS  
 ■ Conduction disease  
 □ Unaffected


Probst et al., 2009






# 2023 : Cardiac arrhythmias genetics ( > 80 genes)

## Long QT Syndrome




**KCNQ1**    **KCNJ2**    **KCNJ5**  
**KCNH2**    **CACNA1C**    **SNTA1**  
**SCN5A**    **CAV3**  
**ANK2**    **SCN4B**  
**KCNE1**    **CALM1**  
**AKAP9**    **KCNE2**

## Short QT




**KCNQ1**  
**KCNH2**  
**KCNJ2**  
**CACNA1C**  
**CACN2B**  
**CACNA2D1**

## Atrial Fibrillation



**KCNQ1**    **SCN5A**  
**SCN3B**    **ANK2**    **ABCC9**    **GJA5**  
**KCNE1**    **KCNE5**    **KCNA5**  
**KCNE2**    **SCN1B**    ...  
**KCNJ2**    **SCN2B**


## Brugada Syndrome (27)



**SCN5A**    **SCN3B**    **ABCC9**  
**KCNE5**    **KCNE3**    **KCNAB2**  
**RRAD**    **KCND3**    **KCNH2**  
**GPD1L**    **HCN4**    **CACNA1C**  
**KCNJ8**    **SLMAP**    **CACNA2D1**  
**CACNB2**    **TRPM4**    **SCN1B**  
**RANGRF**    **SCN2B**


## Early Repolarization Syndrome (6)

**KCNJ8**    **CACNB2**  
**SCN5A**    **CACNA2D1**  
**CACNA1C**    **ABCC9**



**RYR2**  
**CASQ2**  
**TRDN**  
**CALM1**

## Cardiac conduction block



**SCN5A**  
**SCN1B**    **GJA5**  
**TRPM4**    **GJA1**

- Familial rare (linkage/candidate gene)
- Overlap syndrome
- Variable penetrance and expressivity

Arrhythmias gene panel : 109 genes

Centre de référence de Nantes/ Laboratoire de génétique moléculaire

S. Bezieau)

# ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing

The American College of Medical Genetics and Genomics has published recommendations for reporting incidental findings in the exons of certain genes.


Adenomatous polyposis coli (MIM 175100)	APC (MIM 611731)
Aortic aneurysm, familial thoracic 4 (MIM 132900)	MYH11 (MIM 160745)
Aortic aneurysm, familial thoracic 6 (MIM 611788)	ACTA2 (MIM 102620)
Arrhythmogenic right ventricular cardiomyopathy, type 5 (MIM 604400)	TMEM43 (MIM 612048)
Arrhythmogenic right ventricular cardiomyopathy, type 8 (MIM 607450)	DSP (MIM 125647)
Arrhythmogenic right ventricular cardiomyopathy, type 9 (MIM 609040)	PKP2 (MIM 602861)
Arrhythmogenic right ventricular cardiomyopathy, type 10 (MIM 610193)	DSG2 (MIM 125671)
Arrhythmogenic right ventricular cardiomyopathy, type 11 (MIM 610476)	DSC2 (MIM 125645)
Breast-ovarian cancer, familial 1 (MIM 604370)	BRCA1 (MIM 113705)
Breast-ovarian cancer, familial 2 (MIM 612555)	BRCA2 (MIM 600185)
Brugada syndrome 1 (MIM 601144)	SCN5A (MIM 600163)
Catecholaminergic polymorphic ventricular tachycardia (MIM 604772)	RYR2 (MIM 180902)
Dilated cardiomyopathy 1A (MIM 115200)	LMNA (MIM 150330)
Dilated cardiomyopathy 1A (MIM 115200)	MYBPC3 (MIM 600958)
Ehlers-Danlos syndrome, type 4 (MIM 130050)	COL3A1 (MIM 120180)
Fabry's disease (MIM 301500)	GLA (MIM 300644)
Familial hypercholesterolemia (MIM 143890)	APOB (MIM 107730)
	LDLR (MIM 606945)
Familial hypertrophic cardiomyopathy 1 (MIM 192600)	MYH7 (MIM 160760)
Familial hypertrophic cardiomyopathy 3 (MIM 115196)	TPM1 (MIM 191010)
Familial hypertrophic cardiomyopathy 4 (MIM 115197)	MYBPC3 (MIM 600958)
Familial hypertrophic cardiomyopathy 6 (MIM 600858)	PRKAG2 (MIM 602743)
Familial hypertrophic cardiomyopathy 7 (MIM 613690)	TNNI3 (MIM 191044)
Familial hypertrophic cardiomyopathy 8 (MIM 608751)	MYL3 (MIM 160790)
Familial hypertrophic cardiomyopathy 10 (MIM 608758)	MYL2 (MIM 160781)
Familial hypertrophic cardiomyopathy 11 (MIM 612098)	ACTC1 (MIM 102540)
Familial medullary thyroid carcinoma (MIM 155240)	RET (MIM 164761)
Hypercholesterolemia, autosomal dominant, 3 (MIM 603776)	PCSK9 (MIM 607786)
Juvenile polyposis syndrome, (MIM 174900)	BMPR1A (MIM 601299)
Juvenile polyposis syndrome, (MIM 174900)	SMAD4 (MIM 600993)
Left ventricular noncompaction 6 (MIM 601494)	TNNT2 (MIM 191045)
Li-Fraumeni syndrome 1 (MIM 151623)	TP53 (MIM 191170)
Loeys-Dietz syndrome type 1A (MIM 609192)	TGFBR1 (MIM 190181)
Loeys-Dietz syndrome type 1B (MIM 610168)	TGFBR2 (MIM 190182)
Loeys-Dietz syndrome type 2A (MIM 608967)	TGFBR1 (MIM 190181)
Loeys-Dietz syndrome type 2B (MIM 610380)	TGFBR2 (MIM 190182)
Loeys-Dietz syndrome type 3 (MIM 613795)	SMAD3 (MIM 603109)
Long QT syndrome 1 (MIM 192500)	KCNQ1 (MIM 607542)
Long QT syndrome 2 (MIM 613688)	KCNH2 (MIM 152427)
Long QT syndrome 3 (MIM 603830)	SCN5A (MIM 600163)

## ➤ 78 actionable genes


### ■ 19 cardiac diseases

- 15 cardiomyopathies (ARVC, DCM, HCM)
- 4 arrhythmias

- Brugada Syndrome



- Long QT Syndrome (1,2 & 3)




(SCN5A, KCNQ1, KCNH2)

# Gene identification by Exome sequencing

# Cardiac Conduction Defects



- Historically isolated Progressive Cardiac Conduction Defects, the most common form of CCD, (Lenègre & Lev disease) was considered as a structural and degenerative disease mostly due to **aging**, fibrosis in the conduction system



- ◆ **Strong genetic background / genetic heterogeneity:**

- Isolated PCCD: Channelopathy, *SCN5A*, *SCN1B*, *TRPM4*, *GJA5*
- PCCD & Cardiomyopathies: *NKX2.5*, *TBX5*, *PRKAG2*, *LMNA*

- Non-immune isolated Congenital AV block is a rare condition

- Prevalence : 1/15 000
- Immunological compound in 80 % congenital AVB
- Mortality : 30 %




- ◆ **Suspected Strong genetic background**

# Search for new Congenital & early childhood AVB index genes: Strategy

- Patient recruitment:
  - 141 Index cases
    - Diagnosed under age 15 (13 centers in France)

- cAVB – trios



- 15 trios
  - No familial history of AV block
  - Unaffected parents

- Exome sequencing

European Heart Journal Advance Access published September 14, 2011



European Heart Journal  
doi:10.1093/eurheartj/ehr347

CLINICAL RESEARCH

## Characteristics and long-term outcome of non-immune isolated atrioventricular block diagnosed *in utero* or early childhood: a multicentre study

Alban-Elouen Baruteau<sup>1,2,3,4,5,6\*</sup>, Swanny Fouchard<sup>1</sup>, Albin Behaghel<sup>2,3,4,7</sup>, Philippe Mabo<sup>2,3,4,7</sup>, Elisabeth Villain<sup>6,8</sup>, Jean-Benoit Thambo<sup>6,9</sup>, François Marçon<sup>6,10</sup>, Véronique Gournay<sup>6,11</sup>, Francis Rouault<sup>6,12</sup>, Alain Chantepie<sup>6,13</sup>, Sophie Guillaumont<sup>6,14</sup>, François Godart<sup>6,15</sup>, Caroline Bonnet<sup>6,16</sup>, Alain Fraise<sup>6,17</sup>, Jean-Marc Schleich<sup>2,3,4,6,7</sup>, Jean-René Lussion<sup>6,18</sup>, Yves Dulac<sup>6,19</sup>, Christophe Leclercq<sup>2,3,4,7</sup>, Jean-Claude Daubert<sup>2,3,4,7</sup>, Jean-Jacques Schott<sup>1</sup>, Hervé Le Marec<sup>1,20</sup>, and Vincent Probst<sup>1,20</sup>

 Agilent Technologies





# Exome sequencing of 15 trios

## ➤ 19 *de novo* variants

Trio	Gène	Nucléotide	Acide Aminé	Conséquence
0	<i>NSUN6</i>	c.956 C>T	p.R319Q	Faux-sens
1	<i>GCN1L1</i>	G>T		Site d'épissage (intronique)
2	<i>SHBG</i>	c.74G>A	p.R25H	Faux-sens
2	<i>CNTROB</i>	c.137G>A	p.R46Q	Faux-sens
3	<i>USH2A</i>	c.82T>A	p.I28L	Faux-sens
3	<i>SOS2</i>	c.58G>C	p.R20G	Faux-sens
4	<i>GPR107</i>	c.1396C>A	p.L466I	Faux-sens
6	<i>PTGER3</i>	C>A		Site d'épissage (intronique)
7	<i>TTC21B</i>	c.3641 T>C	p.D1214G	Faux-sens
7	<i>C7orf61</i>	c.209 A>G	p.L70S	Faux-sens
8	<i>TEX29</i>	G>C		Site d'épissage (5'-UTR)
9	<i>LPHN2</i>	c.296 A>G	p.N99S	Faux-sens
9	<i>RHOBTB1</i>	c.1259 G>A	p.T420M	Faux-sens
10	<i>RYR2</i>	c.10361 G>A	p.R3454H	Faux-sens
11	<i>ZNF683</i>	c.1219_1226 delCTGCACTG	p.Q407CfsX461	Frameshift & protéine tronquée
11	<i>ZNF22</i>	c.85 C>T	p.Q29X	Gain d'un codon-stop
11	<i>GJC1</i>	c.224 C>T	p.R75H	Faux-sens
11	<i>ATAD2B</i>	c.4212 C>G	p.L1404F	Faux-sens
14	<i>DOPEY2</i>	c.6697 C>T	p.R2233C	Faux-sens



# Variant selection




	Family A (trio11)	Family B
	French case	Japanese case
Target genes for exon capture	All exons (Trio-exome)	457 genes
Coding variations (*)	13,035	1,040
<i>De novo</i> variants	7	NA
MAF<0.1%	4	8
Sanger validation	4	8
Co-segregation	NA	3
Candidate variations	4	3
Common mutation	<i>GJC1</i> -c.G224A, (Cx45-p.R75H)	

\*: nonsynonymous, stop-gain, stop-loss, splice site replacement, or indel frameshift


NA: not applicable

¶; found in the proband (II:1) but not in his parents

# Novel *GJC1* mutation (Cx45-p.R75H)





		64	E1	75	TM2	87
Cx45	Human	CYDAFAPLSHV		<b>R</b>	FWVFQIILVATP	
	Chimp	.....		.	.....	
	Macaca	.....		.	.....	
	Mouse	.....		.	.....	
	Rat	.....		.	.....	
	Dog	.....		.	.....	
	Opossum	.....		.	.....	
Cx43	Human	...KSF.I...		.	...L...F.SV.	
Cx40	Human	...QAF.I..I		<b>I</b>	.Y..L...F.S..	<b>.</b>
Cx26	Human	...HYF.I..I		<b>I</b>	.L.AL.L.F.S..	<b>.</b>
Cx32	Human	...Q.F.I...		<b>I</b>	.L.SL.L...S..	<b>.</b>
Cx46	Human	...RAF.I..I		<b>I</b>	...AL...F.S..	<b>.</b>



- Connexin family of proteins consists of more than **21 members** varying in their biophysical properties


- **CX40, 43, 45** heart specific

Family A




3rd degree AV block & progressive loss of P wave


Family B



II:2  
(9 yo)




III:1  
(8 yo)




(12 yo)




(14 yo)



III:2  
(14 yo)



I:1  
(37 yo)







# In vitro studies

## 1- Normal hemichannel assembly and plaque formation


(Co-IP / Immunofluorescent)




(Immunofluorescent)



## 2- Severe reduction of permeation properties (Luciferase dye transfer)



## 3- Macroscopic conductance (Gj) suppressed in hetero & homomeric channels



➤ Dominant-negative




# In vivo studies



## Electrophysiological properties of conditional *Gjc1* knockout mice



1- Various atrial arrhythmias  
(after tamoxifen administration)




➤ Pathophysiology of Cx45-p.R75H in developmental defects?

Seki et al. J Am Coll Cardiol. 2017


# Whole Genome Sequencing in unresolved mendelian arrhythmias



# A large family associating sinus node dysfunction & long QT syndrome linked to the *ANK2* gene




➤ Loss of function mutation in *ANK2* (*Ankyrin*)




Mohler P; Schott JJ et al. *Nature*. 2003

- 24 affected cases
- 2 sudden death (ventricular arrhythmias)




- Long QT syndrome
- Sinus node dysfunction (SND)
- Atrial fibrillation (AF)

➤ Additional families  
 - with positive linkage at 4q25 locus  
 - **no *ANK2* mutation**



# A large *ANK2*-negative family presenting with a complex cardiac syndrome with positive linkage at 4q25 locus

Family 1



## Electrical cardiac disorders:


Sinus node dysfunction  
Long QT  
Atrial fibrillation

## Cardiac developmental defect:

Atrial septal defect  
Mitral valve prolapse  
LV non-compaction

# WGS Identifies a rare 15 kb deletion in a gene desert area

Family 1



## Electrical cardiac disorders:

Sinus node dysfunction  
Long QT  
Atrial fibrillation

## Cardiac developmental defect:

Atrial septal defect  
Mitral valve prolapse  
LV non-compaction  
Vein abnormalities

### Linkage analysis

4q25 region associated with  
Ankyrin B syndrome  
P.J.Molher et al 2002

### Sanger sequencing

No mutation in *ANK2* gene

### Exome sequencing

No mutation in genes located in  
the 4q25 region

### Whole genome sequencing

Identification of a 15kb  
deletion in a gene desert area




Reduced sequencing depth by 50%



# Identification of a large family presenting with a complex cardiac syndrome associated with a 15 kb deletion in a gene desert area

Family 1



## Electrical cardiac disorders:

- Sinus node dysfunction
- Long QT
- Atrial fibrillation

## Cardiac developmental defect:


- Atrial septal defect
- LV non-compaction
- Vein abnormalities
- Mitral valve prolapse

### *PITX2*

- Cardiac transcription factor essential for the left-right asymmetry of the heart
- Sinoatrial node development
- Risk variants in *PITX2* associated with atrial fibrillation

### *Ank2*

- Localization and membrane stabilization of ion channels
- ANK2* loss-of-function variants are associated with sinus node disease, atrial fibrillation, ventricular arrhythmia, and risk of sudden cardiac death.



Human chr4

1 Mb

hg19

refSeq genes

*ENPEP*  
*PITX2*


*C4orf32*  
*AP1AR*  
*TIFA*  
*ALPK1*  
*NEUROG2*  
*C4orf21*  
*LARP7*

*ANK2*  
*CAMK2D*


Family1 15 kb

## Relevance of this non-coding region to the disease?

# Six additional families (4 French and 2 Japanese) presenting with a similar phenotype showing overlapping deletions



Human chr4  
refSeq genes  
*ENPEP*  
*PITX2*




- Absent in control databases

**Crucial role of this non coding deleted region: regulatory element?**

# Definition of Epigenetics

Every cell-type in an organism contains the same genetic information but has extremely different shapes and functions.




How cells read the genes

<https://www.slideshare.net/hamivia/definition-of-epigenetics>

DNA methylation  
Chromatin structure and modification  
Non-coding RNA (ncRNA)

# Identification of the role of regulatory regions



## 1- ENCODE database: Encyclopedia of DNA Elements

<https://www.encodeproject.org/>

## - Encyclopedia of DNA Elements at UCSC


<https://genome.ucsc.edu/encode/>

## - GENCODE / VISTA ...


## 2- hiPSC (tissue & condition specific)

### 1. Re-programmation

### 2. Differentiation




1




Pluripotent cells




2




Cardiac human cells




# Functional annotation of non-coding region in the 4q25 region









# Functional annotation of non-coding region in the 4q25 region



human  
Ventricle  
CM



hiPS-CM WT




Open region

Active region


Promoter region

Enhancer region



CTCF binding site






# Functional annotation of non-coding region of the genome





## Histone modifications



# Hypothesis: deletion of the CTCF binding site modifies the Topologically Associated Domain (TAD) boundary



Deletion of CTCF  
binding site



# Chromatin Conformation Capture HiC: 3D organization of the 4q25 region




MAX-PLANCK-GESELLSCHAFT



hiPS-CM WT


High  
Low







# 3D chromatin conformation remodeling with 15kb deletion

hiPS-CM WT




hiPS-CM 15Kb deletion



Fusion of the two TADs result in new interactions with *PITX2*




# Mouse model to characterize the impact of the deletion on the phenotype



Human chr4 1 Mb hg19

RefSeq genes





Human-mouse alignable







Mouse Chr3 mm10 1 Mb

RefSeq genes






# Mouse model to characterize the impact of the deletion on the phenotype



No phenotype observed in mice carrying deletion A and C

# In vivo electrical cardiac activity investigation physiology on mice carrying 15kb deletion





CRISPR Mice show slower heart rates, slower sinus node recovery times, atrial arrhythmias

Bradycardia, SND and atrial arrhythmia recapitulates electrical phenotype identified in patients

# Cardiac morphological characterization of mice carrying 15kb deletion





Heart size




WT DelB

ASD Adult  
p=0.0396



ASD  
p=0.036



No deletion Deletion carrier



CRISPR Mice show a slightly bigger heart and ASD

Mouse model recapitulates electrical and morphological cardiac phenotype identified in patients

# Severe disruption of the SAN-specific genetic program coinciding with the induction of ectopic *Pitx2* expression in the SAN



*DelB* SAN tissue



RNA-Seq:



- -suppressed gene expression encoding:
  - **Tbx3** and **Isl1** (key pacemaker TFs)
  - **Hcn4** ion channels that drives pacemaker function

Upregulation of *Pitx2* in the right atria

Downregulation of *Pitx2* & *Ank2* in the ventricles



# Opposite PITX2 expression pattern in ventricle-like cardiomyocytes and pacemaker cell-like cardiomyocytes



# Conclusions

## WGS is a powerful approaches to identify new regulatory elements and target genes

- New cardiac entity: CTCF deletion not found in 39 French patients presenting **lone sinus node defects nor in > 10,000 atrial fibrillation cases**
- Cardiac electrical and structural defects are likely mediated by heart compartment-specific dysregulation of *PITX2* expression
  - suppressed gene expression encoding Tbx3 and Isl1 (key pacemaker TFs), Hcn4 ion channels that drives pacemaker function
- Will / can WGS become the new gold standard / genetic testing?

*Baudic et al. in revision*





# The Brugada syndrome

- ◆ Rare disease (1-5/10 000), affecting mainly men ( $\approx 80\%$ )
- ◆ Mean age of diagnosis around age 40
- ◆ Ventricular tachycardia, ventricular fibrillation **and sudden cardiac death**
- ◆ Baseline condition or after drug challenge
  - Typical pattern of ST segment elevation, on the right precordial leads (V1-V3) of the surface ECG
- ◆ No cardiac structural defects

## ◆ Brugada syndrome is a genetic condition:


- Autosomal dominant disease
- **SCN5A** loss of function mutations in  **$\sim 20\%$  cases**
  - Decreased upstroke velocity of the cardiac action potential
  - Reduced penetrance and variable expressivity
- 22 additional genes (familial and candidate gene approaches)
- Over all contribution to disease prevalence is still unclear
- **Burden testing: only rare SCN5A variants** are significantly associated to BrS



➤ **SCN5A remains a poor marker for SCD risk stratification (BrS, a polygenic disease?)**

# Variable penetrance and expressivity in mendelian diseases

## Brugada Syndrome families with non-mendelian segregation



**Presence of genetic modulators?**

➤ **Role of frequent variants modulating BrS expressivity**



# A GWAS on Brugada syndrome: study design



**383 index cases with  
Brugada Type-1 ECG**



**898 control individuals**



**Axiom Genome-Wide Human CEU-1 Array Plate**

587,352 markers




# Common polymorphisms modulate Brugada syndrome


*L'institut du thorax*  
*in the heart of an international network on Brugada syndrome*



**312 patients**  
**1115 controls**




\* National Referral Centre for Inherited Cardiac Arrhythmias



# Translate genetic findings to molecular mechanisms




## Chromatine conformation



SCN5A



SCN10A



SCN5A


## eQTL

rs6801957 regulates *SCN5A* expression in human myocardium




M. van den Boogaard et al. JCI 2012  
M. van den Boogaard et al. JCI 2014

# Cumulative effect of risk alleles at the three loci



# International Brugada Syndrome Genetics Consortium




**~2800 BrS probands,  
European descent**

Brugada syndrome Genome-wide association meta-analysis



# GWAS: identification of 12 loci associated with Brugada syndrome

## 21 independent association signals (10 new loci)




## New molecular mechanisms

### ➤ BrS heritability ( $h^2$ ):

- ◆ substantial portion of susceptibility to BrS attributable to common genetic variation
- ◆ 0.17 (LDSC) to 0.34 (GREML)





# A predominant role of *SCN5A/SCN10A* locus risk alleles







➤ *SCN5A/SCN10A* locus: 8 independent loci

# Risk haplotypes co-localize at multiple SCN10A / SCN10A intronic enhancers




- Epigenetic marks:
- Histone acetylation, methylation
- TF bindings sites
- 3D chromatin conformation

# SCN10A-Short /Na<sub>v</sub>1.8 modulates sodium currents Na<sub>v</sub>1.5 in HEK293 cells



Increased I<sub>Na</sub> density


# GWAS: identification of 8 loci associated with transcription factors




➤ Implication of TF in regulating ion channels expression in the heart

# TBX5 drives expression of cardiac conduction system function

## TBX5



## rs 883079 eQTL




Arnolds et al. J Clin Invest. 2012

➤ Indirect regulation of Nav1.5 expression by TF




# GWAS: identification of 3 loci associated with structural proteins





➤ new molecular mechanisms

# MAPRE2 is a trafficking protein / regulator of microtubules

(microtubule plus-end binding protein (EB2))



eQTL







➤ EB1 protein, previously described in microtubules-mediated trafficking of connexin in cardiomyocytes

Microtubules-mediated connexin trafficking



S. Xiao & R M Shaw, Trends Cardiovasc Med. 2015

# MAPRE2 is a regulator of microtubule organization and impacts on sodium current



David Chiang  
(Boston)




Mariam Jouni  
(Chicago)




Modulation of microtubule function alters ion-channel trafficking


# Multiple levels of sodium current dosage regulation affects in BrS phenotype




Rare coding mutations  
(loss of function)




**Ion channel control**



**Translational control**



**Post-translational control**




Common non-coding risk alleles


# Impact in clinical practice: PRD and risk allele distribution among cases

## Cumulative effect of susceptibility variants (21 loci)

### Polygenic risk score




## Polygenic Risk Score (PRS) in *SCN5A* +/-





# BrS, a relevant model for more complex diseases





## Genome-wide association meta-analysis identifies novel Brugada Syndrome susceptibility

### loci and highlights multiple pathways modulating ion channel dosage



Julien Barc<sup>1\*</sup>, Rafik Tadros<sup>2,3\*</sup>, Charlotte Glinge<sup>2,4\*</sup>, David Y Chiang<sup>5\*</sup>, Mariam Jouni<sup>6\*</sup>, Floriane Simonet<sup>1\*</sup>, Sean J Jurgens<sup>7</sup>, Manon Baudic<sup>1</sup>, Michele Nicastro<sup>2</sup>, Franck Potet<sup>8</sup>, Joost A Offerhaus<sup>2</sup>, Roddy Walsh<sup>2</sup>, Seung Hoan Choi<sup>7</sup>, Arie O Verkerk<sup>2,9</sup>, Yuka Mizusawa<sup>2</sup>, Soraya Anys<sup>10</sup>, Damien Minois<sup>10</sup>, Marine Arnaud<sup>10</sup>, Josselin Duchateau<sup>11,12,13,14</sup>, Yanushi D Wijeyeratne<sup>15</sup>, Alison Muir<sup>16</sup>, Michael Papadakis<sup>15</sup>, Silvia Castelletti<sup>17</sup>, Margherita Torchio<sup>18</sup>, Cristina Gil Ortuño<sup>19</sup>, Javier Lacunza<sup>20</sup>, Daniela F Giachino<sup>21,22</sup>, Natascia Cerrato<sup>23</sup>, Raphaël P Martins<sup>24</sup>, Oscar Campuzano<sup>25,26,27,28</sup>, Sonia Van Dooren<sup>29,30</sup>, Aurélie Thollet<sup>10</sup>, Florence Kyndt<sup>10</sup>, Andrea Mazzanti<sup>31</sup>, Nicolas Clémenty<sup>32</sup>, Arnaud Bisson<sup>32</sup>, Anniek Corveleyn<sup>33</sup>, Birgit Stallmeyer<sup>34</sup>, Sven Dittmann<sup>34</sup>, Johan Saenen<sup>35</sup>, Antoine Noël<sup>36</sup>, Sherry Honarbakhsh<sup>37</sup>, Boris Rudic<sup>38,39</sup>, Halim Marzak<sup>40</sup>, Matthew K Rowe<sup>41</sup>, Claire Federspiel<sup>42</sup>, Sophie Lepage<sup>43</sup>, Leslie Placide<sup>44</sup>, Antoine Milhem<sup>45</sup>, Hector Barajas-Martinez<sup>46</sup>, Britt-Maria Beckmann<sup>47</sup>, Ingrid PC Krapels<sup>48</sup>, Johannes Steinfurt<sup>49</sup>, Bo Gregers Winkel<sup>50</sup>, Reza Jabbari<sup>51</sup>, Moore B Shoemaker<sup>52</sup>, Carol Ann Remme<sup>2</sup>, Bas J Boukens<sup>9</sup>, Doris Škorić-Milosavljević<sup>2</sup>, Hennie Bikker<sup>53</sup>, Federico C Manevy<sup>2</sup>, Peter Lichtner<sup>54</sup>, Marta Ribasés<sup>55</sup>, Thomas Meitinger<sup>54</sup>, Martina Müller-Nurasyid<sup>56,57,58,59</sup>, KORA-Study Group<sup>60</sup>, Jan H Veldink<sup>61</sup>, Leonard H van den Berg<sup>61</sup>, Philip Van Damme<sup>62</sup>, Daniele Cusi<sup>63</sup>, Chiara Lanzani<sup>64</sup>, Sidwell Rigade<sup>1</sup>, Eric Charpentier<sup>1,65</sup>, Estelle Baron<sup>1</sup>, Stéphanie Bonnaud<sup>1,65</sup>, Simon Lecoïnte<sup>1</sup>, Audrey Donnart<sup>65,1</sup>, Hervé Le Marec<sup>1</sup>, Stéphanie Chatel<sup>1</sup>, Matilde Karakachoff<sup>1</sup>, Stéphane Bézieau<sup>10</sup>, Barry London<sup>66</sup>, Jacob Tfelt-Hansen<sup>67,68,30</sup>, Dan Roden<sup>69,70,71</sup>, Katja E Odening<sup>49,72</sup>, Marina Cerrone<sup>73</sup>, Larry A Chinitz<sup>73</sup>, Paul GA Volders<sup>74</sup>, Maarten P van de Berg<sup>75</sup>, Gabriel Laurent<sup>76</sup>, Laurence Faivre<sup>77</sup>, Charles Antzelevitch<sup>46</sup>, Stefan Kääh<sup>78,79</sup>, Alain Al Arnaout<sup>45</sup>, Jean-Marc Dupuis<sup>43</sup>, Jean-Luc Pasquie<sup>80</sup>, Olivier Billon<sup>42</sup>, Jason D Roberts<sup>41</sup>, Laurence Jesel<sup>40,81</sup>, Martin Borggreffe<sup>38,39</sup>, Pier D Lambiase<sup>82,37</sup>, Jacques Mansourati<sup>36</sup>, Bart Loeys<sup>83</sup>, Antoine Leenhardt<sup>84,30</sup>, Pascale Guicheney<sup>85,86</sup>, Philippe Maury<sup>87</sup>, Eric Schulze-Bahr PhD<sup>34,30</sup>, Tomas Robyns<sup>88,89</sup>, Jeroen Breckpot<sup>33</sup>, Dominique Babuty<sup>32</sup>, Silvia G Priori<sup>31,30</sup>, Carlo Napolitano<sup>31,30</sup>, Nantes Referral Center for inherited cardiac arrhythmia<sup>90</sup>, Carlo de Asmundis<sup>91,92,27,30</sup>, Pedro Brugada<sup>93</sup>, Ramon Brugada<sup>94</sup>, Elena Arbelo<sup>95</sup>, Josep Brugada<sup>96</sup>, Philippe Mabo<sup>24</sup>, Nathalie Behar<sup>97</sup>, Carla Giustetto<sup>23</sup>, Maria Sabater Molina<sup>19</sup>, Juan R Gimeno<sup>20,30</sup>, Can Hasdemir<sup>98</sup>, Peter J Schwartz<sup>17,30</sup>, Lia Crotti<sup>99,30</sup>, Pascal P Mckeown<sup>100</sup>, Sanjay Sharma<sup>15</sup>, Elijah R Behr<sup>15,30</sup>, Michel Haissaguerre<sup>11,12,13,14</sup>, Frédéric Sacher<sup>11,12,13,14</sup>, Caroline Rooryck<sup>101,102</sup>, Hanno L Tan<sup>103</sup>, Pieter G Postema<sup>2</sup>, Mario Delmar<sup>104</sup>, Patrick T Ellinor<sup>105</sup>, Steven A Lubitz<sup>105</sup>, Jean-Baptiste Gourraud<sup>10</sup>, Michael WT Tanck<sup>106</sup>, Alfred L George, Jr.<sup>107</sup>, Calum A MacRae<sup>108</sup>, Paul W Burridge<sup>109,110</sup>, Christian Dina<sup>1</sup>, Vincent Probst<sup>10,30\*</sup>, Arthur A Wilde<sup>2,30\*</sup>, Jean-Jacques Schott<sup>10\*</sup>, Richard Redon<sup>10\*</sup>, Connie R Bezzina<sup>2\*</sup>

nature  
genetics

Barc et al.2022 Mar;54(3):232-239



## Further perspectives (GWAS)




- 1- A first Genome-wide association meta-analysis **of Japanese ancestry**: 940 BrS cases and 1,634 controls
- 2- Genome-wide association meta-analysis combining the Japanese and the European-ancestry datasets: **3,760 BrS cases** and 11,635 controls
  - **17 loci** reached the genome-wide significance
  - **5 loci** were newly discovered in the cross-ancestry meta-analysis.
  - **Polygenic risk score analysis highlights shared genetic architecture across ancestries**
- 3- **Genome-wide analysis of lethal arrhythmic events among BrS patients identifies 1 VF-associated SNP in Japanese and European BrS**

# Whole genome sequencing accurately identifies CNVs



→ ECG de type I Brugada

3 syncopes → ICD at age 45




50% reduction of coverage  
→ hétérozygote deletion

➤ **10 kb deletion in the promoter region of *SCN5A***

# Functional annotation




# Functional annotation of the deletion region



Potential 2 opened chromatin regions



H3K27 : active  
H3K4me1 : enhancer  
→ active enhancer

# Functional annotation of the deletion region






# Functional annotation of the 10kb deletion (patch clamping)




➤ Reduction of  $I_{Na}$  density

# Multiple levels of sodium current dosage regulation affects in BrS phenotype



**Normal sodium current**


Rare coding mutations



**Reduced sodium current**


Common non-coding risk alleles

**Ion channel control**




**Reduced sodium current**

**Translational control**



**Reduced sodium current**

**Post-translational control**



*MAPRE2*

**Reduced sodium current**

**Ion channel control**



**Reduced sodium current**

## Key take-home messages


- The inheritance model for Brugada syndrome is complex
- Unexpected large effect of common genetic variations on BrS susceptibility
- **The *SCN5A* locus is prominent in disease susceptibility, with strong involvement in both rare and common alleles**
- Strong involvement of transcription regulation impacting ion channels expression, heart development **as well as cardiac structural anomalies**

➤ **THERAPY: From ICD & pharmacology to genetic testing and personalized medicine ?**


- RARE & COMMON VARIANT: GENETIC RISK SCORE
- New pharmacological approaches targeting gene regulatory region?

CORRESPONDENCE


(Nov. 2018)



A Novel Familial Cardiac Arrhythmia Syndrome with Widespread ST-Segment Depression



A 12-Lead ECG of the Family A Proband




➤ The index patient incidental presentation at 36 years of age with an ECG showing deep and **persistent, concave-upward ST-segment depression** in leads I, II, aVL, aVF, and V2 through V6


➤ Five unrelated families (rare phenotype)

No gene(s) identified (panel, exome, genome...)


# Similar ECG pattern in an isolated case in Nantes



- The 9 y/o index patient (female) presenting cardiac arrest
- Initial diagnostic: Brugada syndrome
- **ECG showing deep and persistent, concave-upward ST-segment depression in leads (unrecognized)**
- Unresponsive to antiarrhythmic medication
- ICD implantation / multiple shocks
- Unresponsive to ventricular ablations
  - Cardiogenic shock
- Heart transplant




- Both parents are unaffected (normal ECGs)
- Whole genome sequencing (trio)
  - *de novo* mutation ?






# A de novo mutation in DES (desmin) gene





**DES p.Arg406Trp**

Ultra-rare (not found in GnomAD)


- Same DES p.Arg406Trp mutation with similar ECG



- Severe rhythm disorder
- Died at 6 months of age in the cardiopediatric emergency care



**Intercalated disk**





## DES p.ARg406Trp mutation is an ultra rare variant but report in the literature

- *de novo*, in 2 other cases (no ECG) in literature & 1 with HCM & complete AV block and ST segment depression
- 1 with familial segregation (father and son; no ECGs documented)

## Is DES DES p.ARg406Trp a Desminopathy?

- subgroup of myofibrillar myopathies affecting both skeletal and cardiac muscles
- **50% of mutations carriers have cardiomyopathy**: dilated (17%), restrictive (12%), hypertrophic (6%), arrhythmogenic right ventricular (1%) cardiomyopathies
- 60% have cardiac conduction disease or arrhythmias, with atrioventricular block as a hallmark

## Index case

- 2009: no structural heart disease (2-D echography) or anomalies of the coronary arteries (tomography)
- Histopathological examination of the explanted heart :
  - increased amounts of epicardial fat, mainly in RV, no fibro-fatty replacement, no dystrophic cardiomyocytes → not an ARVC

March 2021: no clinical sign of skeletal muscle disease at 23 years old


# Functional analysis

## Impact of DESp.R406W on cardiac cells



Michelle Geryk  
(F. Charpentier's team)

→ iPS model (ventricular CM: 2D and Engineered Heart Tissue (EHT))



# Next steps

- **Electrophysiological studies**
  - **Patch clamping**
    - **Action potential recording unchanged**
  - **Abnormal mitochondria distribution & structure**
    - **Additional models**
      - **Mouse model (ongoing)**
      - **Purkinje cells (no iPS model)**

# Perspectives: from NGS to Digital Health

## ENTERING THE BIG DATA ERA

- High throughput multi-omics approaches
  - ✓ Whole genome sequencing
  - ✓ Epigenetic
  - ✓ Single cell RNA sequencing
- Digital enhanced **phenotyping**
  - ✓ MRI
  - ✓ ...

## Artificial Intelligence



## NEW HYPOTHESIS

New biological insights

**Better risk stratification**